Linezolid for multidrugresistant tuberculosis
In their Comment in The Lancet Infectious Diseases, Kwok-Chiu Chang and colleagues 1 concluded that expansion of access to linezolid for complicated cases of drug-resistant tuberculosis risks the loss of a potentially useful drug and could promote the emergence and spread of drug-resistant tuberculosis in the community. The rationale behind this idea seems to be the scarcity of controlled clinical trials and, in particular, data for optimum linezolid dose. Although we agree that the evidence base is small, our recent systematic review 2 suggests that good outcomes can be achieved with linezolid among patients who would otherwise have very poor outcomes and high mortality. Among 148 patients treated with linezolid, the rate of treatment success (68%) was at least as good as that expected for multidrug-resistant tuberculosis treatment overall (62%). 2, 3 None of the authors of the studies included in that review advocates large-scale and indiscriminate use of linezolid for drugresistant tuberculosis. Conversely, in view of the poor side-eff ect profi le and treatment complexity, linezolid is recommended for patients with few remaining treatment options, treated in well functioning programmes.
The risk of emerging drug resistance is relevant, but no more so than for other second-line drugs presently used for drug-resistant tuberculosis. Existing treatment regimens are lengthy, are associated with sub stantial side-eff ects, and result in overall poor outcomes. Unfortunately, controlled trials to defi ne better regimens are scarce. However, failure to scale up treatment access will lead to continued community transmission and worsening of the epidemic. 4 Newer derivatives of linezolid with improved side-eff ect profi les are under development.
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Meanwhile, linezolid should be available for patients with few treatment options, owing to either extensive drug resistance or previous treatment failure. We have started fi ve patients on strengthened linezolid and clofazimine-containing regimens in Khayelitsha, South Africa, all of whom produced negative sputum cultures within 3 months. Subsequent linezolid withdrawal was necessary in one patient because of severe peripheral neuropathy. Although side-eff ects need to be monitored and managed carefully, the restricting factor in the use of linezolid in our setting, where Pfi zer holds a patent, is cost, rather than scarcity of evidence. In South Africa, linezolid is available in the public sector at a cost of US$1000 per patient per month.
Although improved access to linezolid alone will not solve the worldwide drug-resistant tuberculosis crisis, facilitation of access to new and repurposed drugs for drugresistant tuberculosis will contribute to the overall goal of a shorter, more tolerable, and more eff ective treatment regimen than is available at present, and will off er the hope of cure to patients who would otherwise die.
We declare that we have no confl icts of interest. 
Authors' reply
In our recent Comment, 1 we concluded that a "non-expensive and non-proprietary source of linezolid is insufficient to tackle the evolving global crisis of drug-resistant tuberculosis". This conclusion was not simply based on "scarcity of controlled clinical trials and, in particular, data for optimum linezolid dose", as suggested by Helen Cox and colleagues. Rather, the rationale was the difficult lessons that mankind has learned since anti-tuberculosis chemotherapy became available, especially in view of the wide social divide between rich and poor people, both within and between countries. We added a note of caution against the "introduction of linezolid on a large scale without careful planning or a wellfunctioning health infrastructure", 1 which was reiterated by Cox and colleagues when they also suggested that "in view of the poor side-effect profile and treatment complexity, linezolid is recommended for patients with few remaining treatment options, treated in well functioning programmes".
For people who are unaware of the problems in translation of anecdotal treatment efficacy into an actual public health effect, and the crucial need to promote treatment adherence by direct observation, Although the high cost of linezolid might have hindered its proper use, this factor has probably also reduced its indiscriminate use outside the programme setting. Whereas a pooled proportion of treatment success of 68% among patients with multidrug-resistant tuberculosis treated with linezolid is at least as good as the expected success rate of 62%, 4 this figur e still falls substantially short of treatment success rates reported for drug-susceptible tuberculosis. This fact emphasises the need for other essential elements to achieve fully effective disease control.
To tackle drug-resistant tuberculosis, we need large-scale imple mentation of an eff ective tuberculosis control programme built on the directly observed treatment short-course strategy, supported by proper regulation of high-quality drug supply and a well funded health infrastructure, including funda mental laboratory diagnostic services. Although linezolid might be the most promising repurposed agent in the treatment of complicated multidrug-resistant tuberculosis, its indiscriminate or unsupervised use still creates a major risk of treatment failure and further amplifi cation of drug resistance. Since several new drugs are now at an advanced stage of development, assessment of their clinical roles alongside linezolid in controlled clinical trials in a well functioning programme could be valuable.
We declare that we have no confl icts of interest. Daclatasvir belongs to a class of new directly acting antivirals that inhibit non-structural protein NS5A, inhibiting hepatitis C virus RNA replication. Daclatasvir has inhibitory activity against hepatitis C virus, with broad genotypic coverage and a pharmacokinetic profi le that supports once-daily dosing. 2, 3 Emerging drug-resistant hepatitis C virus variants have been reported previously in patients given daclatasvir in phase 1 monotherapy studies. 3 However, as Pol and colleagues showed, 1 an appropriate dose of daclatasvir, combined with peginterferon alfa-2a and ribavirin, suppresses resistant virus variants, and results in a more rapid and earlier decrease in plasma hepatitis C virus RNA than does dual peginterferon alfa-2a and ribavirin treatment. This randomised, multicentre, doubleblind, placebo-controlled phase 2a trial showed that patients given daclatasvir, mainly at a 10 mg or 60 mg dose, had a better extended rapid virological response at both 4 and 12 weeks of treatment, and a better sustained virological response at 24 months, than did those in the group given peginterferon alfa-2a plus ribavirin. Moreover, the investigators reported no diff erences in side-eff ects between the two treatment groups.
Although the treatment of children with chronic hepatitis C is controversial, daclatasvir's good tolerability and the favourable eff ects of its combination with peginterferon alfa-2a plus ribavirin (triple therapy) encourage clinical trials in children, as suggested by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN). 4 Because no data exist for the toxicology of daclatasvir in children, a phase 1 clinical trial should be a prerequisite for a phase 2 trial; however, Pol and colleagues' results support the possibility of a randomised, multicentre, blinded, placebo-controlled, dose-escalation phase 1-2 clinical trial being started. 48 children (age range 6-17 years) with chronic hepatitis C genotype 1 infection and with the eligibility criteria re commended by NASPGHAN 4 could be included in the trial. The patients should then be randomly assigned (1:1:1:1) into four groups, including 3 mg, 10 mg, and 30 mg doses of oral daclatasvir once daily, and a placebo. The recommended length of therapy is at least 48 months, and all 48 patients should receive once-weekly injections of 60 μg/m² peginterferon alfa-2a and 15 mg/kg per day of oral ribavirin.
